Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOMIRA RESEARCH (BIOM) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (25)	12/20/1999 9:32:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 72

Today's news further confirms the progress of BLP25 into the second half of its phase II study. This study was initiated only six months ago. Thus the second half of the study could be fully enrolled in a similar timeframe. Given this timeframe and the deadly nature of the disease (i.e.progresses so rapidly from diagnosis to almost universally lethal outcomes). This drug (and it's IL2 combo drug) could conceivably prgress to "later stage trials" such as pivitol phase II or even phase III status inside of one year from now. For those unfamiliar go to archives and look up the milestones here, this is moving quickly. Also please recall that the published pre-clinical studies in murine models would easily rival the results that got ENMD up to 25$ a share and beyond. This trial advaces both the BLP25 vaccine and the Liposomal Il-2 drug, that could be used either as stand alone (Il-2 is approved for kidney cancer as a stand alone) or as a combo with BLP25 or many other vaccines including in particular AIDS vaccines. Todays news and the accelerating timelines for this drug are a further indication that BIOM his hitting on all cylinders these days.